Blog
RSS FeedPosted by Michael Wonder on 05 Aug 2015
The pCODR program is moving
Effective April 1, 2015, the pCODR office will be moving to a new location in downtown Toronto -just a few ...
Posted by Michael Wonder on 05 Aug 2015
NICE has issued new preliminary draft guidance that does not recommend bosutinib (Bosulif) for previously treated CML
[:content [\N \I \C \E \space \h \a \s \space \i \s \s \u \e \d \ \n \e \w \space \p \r \e \l \i \m \i \n \a \r \y \space \g \u \i \d \a \n \c \e \ \t \h \a \t \space \d \o \e \s \space \n \o \t \space \r \e \c \o \m \m \e \n \d \space \P \f \i \z \e \r \' \s \space \b \o \s \u \t \i \n \i \b \space \( \B \o \s \u \l \i \f \) \space \f \o \r \space \p \a \t \i \e \n \t \s \space \w \i \t \h \ \p \r \e \v \i \o \u \s \l \y \space \t \r \e \a \t \e \d \space \c \h \r \o \n \i \c \space \m \y \e \l \o \i \d \space \l \e \u \k \a \e \m \i \a \space \( \C \M \L \) \. \ \B \o \s \u \t \i \n \i \b \space \i \s " ..."]]
Read more →
Posted by Michael Wonder on 05 Aug 2015
Quebec becomes the first province to fund Gazyva for patients with most common form of leukaemia
People in Quebec living with chronic lymphocytic leukaemia (CLL) will now be able to access a new treatment option through the province's ...
Posted by Michael Wonder on 05 Aug 2015
Cell Therapeutics provides an update on NICE's appraisal of pixantrone for patients with non-Hodgkin's lymphoma
[:content [\C \e \l \l \space \T \h \e \r \a \p \e \u \t \i \c \s \space \( \C \T \I \) \space \h \a \s \ \a \n \n \o \u \n \c \e \d \space \t \h \a \t \space \t \h \e \space \N \I \C \E \ \h \a \s \space \n \o \t \i \f \i \e \d \space \C \T \I \space \a \n \d \space \i \s \s \u \e \d \space \a \space \s \t \a \t \e \m \e \n \t \space \o \n \space \i \t \s \space \w \e \b \s \i \t \e \space \s \t \a \t \i \n \g \space \t \h \a \t \space \C \T \I \' \s \space \p \r \o \p \o \s \e \d " ..."]]
Read more →
Posted by Michael Wonder on 05 Aug 2015
Giotrif (afatinib) approved by Health Canada as a treatment for patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s) who are tyrosine kinase inhibitor naïve
[:content [\B \o \e \h \r \i \n \g \e \r \space \I \n \g \e \l \h \e \i \m \space \( \C \a \n \a \d \a \) \space \L \t \d \. \space \h \a \s \space \a \n \n \o \u \n \c \e \d \space \t \h \a \t \space \H \e \a \l \t \h \space \C \a \n \a \d \a \space \h \a \s \space \a \p \p \r \o \v \e \d \space \G \i \o \t \r \i \f \ \( \a \f \a \t \i \n \i \b \) \space \t \a \b \l \e \t \s \space \f \o \r \space \o \r \a \l \space \u \s \e \, \space \a \s \space \a \space \n \e \w \space \t \r \e \a \t \m \e \n \t " ..."]]
Read more →
Posted by Michael Wonder on 05 Aug 2015
Germany's IQWiG has found that pertuzumab (Perjeta) has significant added value in certain patients with advanced breast cancer
[:content [\P \e \r \t \u \z \u \m \a \b \space \( \P \e \r \j \e \t \a \) \ \w \a \s \space \l \a \u \n \c \h \e \d \space \i \n \space \G \e \r \m \a \n \y \space \i \n \ \M \a \r \c \h \space \2 \0 \1 \3 \space \f \o \r \space \u \s \e \ \a \s \space \a \d \j \u \n \c \t \i \v \e \space \t \h \e \r \a \p \y \space \b \y \space \c \e \r \t \a \i \n \space \p \a \t \i \e \n \t \s \space \w \i \t \h \space \a \d \v \a \n \c \e \d \ \H \E \R \2 \- \p \o \s \i \t \i \v \e \space \b \r \e \a \s \t \space \c \a \n \c \e \r \. \ " ..."]]
Read more →
Posted by Michael Wonder on 05 Aug 2015
Stakeholder engagement session Phase II of the transfer of pCODR to CADTH
CADTH is inviting stakeholders to attend an information and feedback session on 5 February 2015 regarding phase II of the ...
Posted by Michael Wonder on 05 Aug 2015
SMC rejects Novartis' full submission for everolimus (Afinitor) for women with breast cancer
Everolimus (Afinitor) is not recommended for use within NHS Scotland for the treatment of hormone receptor-positive, human epidermal growth factor type
...Posted by Michael Wonder on 05 Aug 2015
Merck’s Keytruda (pembrolizumab) receives conditional approval in Canada for the treatment of advanced melanoma
Merck Canada Inc. announced today that Keytruda (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. ...
Posted by Michael Wonder on 05 Aug 2015
Zytiga (abiraterone acetate) now available for men with metastatic prostate cancer in British Columbia prior to chemotherapy
[:content [\2 \1 \space \N \o \v \e \m \b \e \r \space \2 \0 \1 \3 \space \â \€ \“ \space \E \f \f \e \c \t \i \v \e \space \1 \5 \space \N \o \v \e \m \b \e \r \space \2 \0 \1 \3 \, \space \B \r \i \t \i \s \h \space \C \o \l \u \m \b \i \a \space \i \s \space \t \h \e \space \f \i \r \s \t \space \p \r \o \v \i \n \c \e \space \i \n \space \C \a \n \a \d \a \ \t \o \space \i \n \c \l \u \d \e \space \Z \y \t \i \g \a \ \( \a \b \i \r \a \t \e \r \o \n \e \space \a \c \e \t \a \t \e \) \space \o \n " ..."]]
Read more →
Posted by Michael Wonder on 05 Aug 2015
Aprecia Pharmaceuticals receives FDA acceptance for filing for first product using advanced ZipDose technology
Aprecia Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug ...
Posted by Michael Wonder on 05 Aug 2015
Health Canada approves new indication for the use of Xtandi (enzalutamide) capsules for patients with metastatic castration-resistant prostate cancer
Astellas Pharma Canada, Inc., the Canadian subsidiary of Tokyo-based Astellas Pharma, Inc., announced today that Health Canada has approved a ...
Posted by Michael Wonder on 05 Aug 2015
BC cancer agency adds Kadcyla to the provincial formulary for the treatment of HER2-positive metastatic breast cancer
Women with HER2-positive metastatic breast cancer in British Columbiawill now be able to access a new treatment option through the BC ...
Posted by Michael Wonder on 05 Aug 2015
pCODR recommends the funding of trastuzumab emtansine (Kadcyla) for female patients with HER-2 positive breast cancer
[:content [\1 \0 \space \J \a \n \u \a \r \y \space \2 \0 \1 \4 \space \- \space \T \h \e \space \p \C \O \D \R \space \E \x \p \e \r \t \space \R \e \v \i \e \w \space \C \o \m \m \i \t \t \e \e \space \( \p \E \R \C \) \space \h \a \s \space \r \e \c \o \m \m \e \n \d \e \d \space \t \h \e \space \f \i \n \d \i \n \g \space \o \f \space \t \r \a \s \t \u \z \u \m \a \b \space \e \m \t \a \n \s \i \n \e \space \( \K \a \d \c \y \l \a \) \space \f \o \r \space \p \a \t \i \e \n \t \s " ..."]]
Read more →
Posted by Michael Wonder on 05 Aug 2015
pCODR recommends the funding of dabrafenib mesylate (Tafinlar) for patients with malignant melanoma
[:content [\5 \space \D \e \c \e \m \b \e \r \space \2 \0 \1 \3 \space \- \space \T \h \e \space \p \C \O \D \R \space \E \x \p \e \r \t \space \R \e \v \i \e \w \space \C \o \m \m \i \t \t \e \e \space \( \p \E \R \C \) \space \h \a \s \space \r \e \c \o \m \m \e \n \d \e \d \space \t \h \e \space \f \u \n \d \i \n \g \space \o \f \space \d \a \b \r \a \f \e \n \i \b \space \m \e \s \y \l \a \t \e \space \( \T \a \f \i \n \l \a \r \) \space \i \n \space \C \a \n \a \d \a " ..."]]
Read more →